2012
Proprotein Processing, Trafficking & Secretion. Chair: Lloyd D. Fricker Vice Chair: John W. Creemers. Gordon research Conference. Colby-Sawyer College New London, NH July 15-20, 2012 http://www.grc.org/programs.aspx?year=2012&program=proproc
Proteolysis: The Most Important Post Translational Modification Regulating Biology, Life and Death of Every Cell. Proteolytic Enzymes & Their Inhibitors. Chair: Klaudia Brix Vice Chair: James C. Whisstock. Il Ciocco Hotel and Resort Lucca (Barga), Italy June 17-22, 2012 http://www.grc.org/programs.aspx?year=2012&program=protenz
The various biological functions of the proprotein convertases and their implications in viral infections. Department of Microbiology & Immunology, Cornell University. Ithaca New York, April 23, 2012 http://instruct1.cit.cornell.edu/research/whittakerlab/
The physiological roles of PCSK9 and its targeting strategies for lipid lowering. Workshop on Novel lipid-lowering strategies. XVI International Symposium on Atherosclerosis. Sydney, Australia, March 25-29, 2012 http://www.isa2012.com/pdf/ISA2012_Program.pdf
The biology and pathophysiology of the proprotein convertases. Hemovascular Group at the Lady Davis Institute, Sir Mortimer B. Davis Jewish General Hospital. March 16, 2012
2011
La saga des proprotéines convertases: fonctions physiologiques et pathologiques. Journée Phare. Université de Sherbrooke, department de Pharmacologie. Hôtel Chéribourg, Magog, Québec, November 4, 2011 http://www.journeephare.com/
Novel insights into the physiological functions of the proprotein convertases. 7th General Meeting of the International Proteolysis Society. San Diego, California, October 16-20, 2011 http://www.ips2011.org/Speakers.html#seidah
Is reduction of PCSK9 levels a promising therapy for atherosclerosis?: in vivo models and novel approaches to silence PCSK9. National Atherosclerosis Forum. Montreal, October 13-14, 2011
Les proprotéines convertases et leurs implications pathologiques incluant le cancer et la métastase. FRSQ-INSERM, UMRS 940, Paris Sept. 28-Oct. 6, 2011
The implication of the proprotein convertases in health and diseases. Seminar, Duke University, Durham, NC, Sept. 20-22, 2011 http://calendar.duke.edu/events/index?user_date=09%2F21%2F2011
La nouvelle odyssée du cholesterol. Café scientifique, Montréal, Québec, June 14, 2011
Invited Speaker: “Les proprotéines convertases dans le cancer et la métastase : Nouvelles cibles thérapeutiques”. Programme Champlain 62.102; INSERM, UMRS 940, Paris May 13-21, 2011
The functional and translational biology of the proprotein convertases. Vascular Biology seminar series. Kidney Research Centre, Ottawa, March 23, 2011. http://www.ohri.ca/newsroom/seminars_short.asp?Program=Vascular
The proprotein convertases: multiple physiological functions and clinical implications. Institut for Cellulær og Molekylær Medicin, Københavns Universitet, Denmark, March 11-15, 2011 http://icmm.ku.dk/Forskergrupper/CCG/meetings/invited_speakers/
The roles of the proprotein convertases in the metabolic syndrome. Montreal Diabete Research center, 5th MDRC. Montreal, January 28, 2011
The proprotein convertases: 20 years later. Killam Seminar, MNI Montreal Jan 25, 2011 http://apps.mni.mcgill.ca/killam10.htm
PCSK9: from cellular and molecular biology to translational applications. Shifa Biomedical Corporation, Malvern, Pensylvannia. January 10, 2011
2010
PCSK9 and lipid metabolism. NAF National Atherosclerosis Forum, Montreal, Quebec, Sept. 30 – Oct 2, 2010 https://enaf.ca/Discussion leader: Session - Proprotein convertases and cardiovascular disease. GRC of Proprotein Processing, Trafficking & Secretion. GRC on Proprotein Processing, Trafficking and Secretion, Colby-Sawyer College, New London, NH. July 18-23, 2010 GRC New LondonNovel insights into the physiological functions of PCSK7. GRC of Proprotein Processing, Trafficking & Secretion, Colby-Sawyer College, New London, NH. July 18-23, 2010 GRC New LondonKeynote Speaker: Jacques Benoit Lecture The secretory proprotein convertases: critical roles in the neuroendocrine axis & implications in pathophysiological disorders. International Society of Neuroendocrinology. Rouen, France. July 11-15, 2010 Jacques Benoit LectureNovel developments in our understanding of PCSK9 functions. Seminar at Bristol Myers Squibb , Princeton, NJ. May 12-13, 2010Novel developments in our understanding of the PCSK9-enhanced degradation of the LDLR and other receptors. GRC of Proteolytic Enzymes & Their Inhibitors. Lucca (Barga), Toscona, Italy. May 2-7, 2010 GRC ItalyThe proprotein convertases: from molecular and cell biology to in vivo functions and therapy. Seminar in Cell Biology. Jacobs University, Bremen, Germany. April 30, 2010 Seminar - Univ. BremenThe proprotein convertases: from cellular functions to in vivo applications. Seminar in Biological Chemistry. University of Michigan Medical Center, Ann Arbor, MI. April 27, 2010 Seminar - Univ. MichiganFrom cellular biology to physiological implications: a tale of two convertases. Retraite scientifique des chercheurs de l’IRCM. Hôtel Estrimont, Orford, March 26, 2010 Retraite des chercheurs IRCMDu cholestérol 101 aux dernières découvertes. Scientific coffee. Montreal. March 22, 2010 Café scientifique
PCSK9-enhanced degradation of receptors: cellular pathways. PCSK9 Conference: from gene to therapeutics. Nantes, France. March 11-13, 2010 PCSK9 ConferenceThe proprotein convertases SKI-1/S1P and PCSK9: from cholesterol metabolism to viral infection. Merck Frosst. Montreal, QC, Canada. January 22, 2010
2009Insights into the Function and Regulation of PCSK9. Deuel Conference on Lipids. La Casa Borrego Springs, CA. March 3 – 5, 2009 Deuel Conference The proprotein convertases in health and disease. Department of Physiology and Biophysics, Dalhousie University Dalhousie Halifax. June 11-12, 2009 Seminar Univ DalhousiePCSK9 and cardiovascular diseases. Crossroad for BioTransfer 2009, University of Montreal. May 5, 2009PCSK9 biology and clinical applications. Merck. Rahway New Jersey. July 15, 2009Dissection of the PCSK9-induced degradation pathways of the LDLR. 11th National Atherosclerosis Forum. Montreal, Quebec, Canada. Sept. 25-26, 2009 National Atherosclerosis ForumPCSK9 and Hepatitis C infection. IRCM lectures of the Cardiovascular and Metabolic Disease axis. Montreal, Quebec, Canada. October 1st, 2009 Axe des maladies cardiovasculaires et métaboliquesRole of the proprotein convertases in viral infections. 8th ICAV Symposium. Corsica, France. October 2-7, 2009 International Consortium AntiviralsPCSK9: a proprotein convertase implicated in dyslipidemia. Canadian Lipoprotein Conference. Windsor, Ontario. October 15-18, 2009The proprotein convertases: structure-function and in vivo functions. Structural Genomics Consortium. Toronto, November 10-11, 2009La proprotéine convertase PCSK9: LDL-cholestérol et infections virale et parasitaire. Centre Hospitalier Universitaire Pitié-Salpêtrière. November 27, 2009
2008The proprotein convertases and their roles in neuroendocrine dysfunctions.Wyeth Neuroscience Discovery, Princeton, January 28-29, 2008The physiological and pathological functions of the proprotein convertases: emphasis on PCSK9. Rinat Neuroscience, Pfizer Global Research and Development, San Francisco, March 7, 2008What did we learn so far from the in vitro and in vivo studies of the proprotein convertases? Retraite scientifique des chercheurs de l’IRCM. Hôtel Mont-Gabriel, Ste-Adèle, April 17,18, 2008 Retraite Chercheurs IRCM The Proprotein Convertases Affect Viral Infection in a Variety of Ways. ICAV Sixth Symposium, Toronto, May 3 – 6, 2008 International Consortium AntiviralsThe role PCSK9 in liver and gut. Bristol Myers Squibb, Princeton, NJ, May 7-8, 2008The role the proprotein convertases in the homeostasis of cholesterol: emphasis on PCSK9. Santaris Pharmaceuticals, Copenhagen, Denmark, May 25-27, 2008Sterol regulation by the proprotein convertases. Zora Biosciences, Espoo, Finland, May 27-29, 2008Furin, PC5/6 and PCSK9 in health and disease. GRC Lipoprotein Metabolism Waterville Valley, New Hampshire June 22-27, 2008 GRC LipoproteinDiscussion leader: Session The Role of Proteolysis in Lipid metabolism. GRC on Proteolytic Enzymes and their Inhibitors, Colby-Sawyer College, New London, NH , July 6-11, 2008 GRC Proteolytic Enzymes and thier inhibitorsImplication of the proprotein convertases in cardiovascular disorders and beyond. GRC on Proteolytic Enzymes and their Inhibitors, Colby-Sawyer College, New London, NH, July 6-11, 2008 GRC Proteolytic Enzymes and thier inhibitorsDiscussion leader: Session - Convertases in Dyslipidemia and PathogenInfections; Pathophysiology. GRC on Proprotein Processing, Trafficking and Secretion, Colby-Sawyer College, New London, NH, July 13-18, 2008 GRC New London (Proprotein Processing Trafficking and secretion)Lessons from convertase knockout mice. GRC on Proprotein Processing, Trafficking and Secretion, Colby-Sawyer College, New London, NH, July 13-18, 2008 GRC New LondonThe proprotein convertases and dyslipidemia. 10th National Atherosclerosis Forum. Toronto. Sept. 26-28, 2008 National Atherosclerosis ForumThe proprotein convertases in health and disease: from genotype to phenotype. ISREC, School of Life Sciences. Ecole Polytechnique Fédérale de Lausanne. Epalinges, Switzerland, Oct. 24 – 26, 2008 IRSEC Seminaire
The proprotein convertases in health and pathology : in vivo validation of a genetic correlation. 2nd Al-Ain International Genetics Conference Al-Ain, United Arab Emirates October 27-30 2008 Dubai: International Genetics ConferenceSession Chairman: New Approaches to Drug Discovery Avian Influenza – Science & Policy International Consortium Antiviral (ICAV) Bejing, China, Nov 1- 7, 2008 International Consortium AntiviralsThe proprotein convertase PCSK9 reduces the level of cell surface LDLR and CD81 and impedes Hepatitis C viral infection. International Consortium Antiviral (ICAV) Bejing, China. Nov 1- 7, 2008 International Consortium Antivirals
